Trading Statement Q1-2025: A Landmark Deal for GUBamy

About this update from Gubra A/s

[{"type":"text","content":"HØRSHOLM, DK / ACCESS Newswire / May 9, 2025 / Gubra (CPH:GUBRA) - Today, Gubra releases its results for the first quarter of 2025. The key development in the quarter was the out-licensing agreement to AbbVie for our anti-obesity asset GUBamy (Amylin). A landmark deal worth USD 2.2 billion in upfront and milestones plus royalties. As part of our strategy toward 2030, we also diverted more resources in the quarter to our D&P business. For the CRO business, revenue amounted DKK 51 million, slightly below corresponding quarter last year. Financial outlook for 2025 is maintained.","length":586,"tagName":"p"},{"type":"text","content":"Henrik Blou, CEO of Gubra said:","length":31,"tagName":"p"},{"type":"text","content":"A landmark deal for GUBamy"In the first quarter, we struck the biggest out-licensing deal so far for Gubra. The partnership with AbbVie really underscores Gubra's expertise in the metabolic space and our ability to develop novel peptide-based therapeutics. The collaboration accelerates the development of GUBamy by building upon AbbVie's immense clinical development expertise and global commercialization footprint. In essence, a collaboration that combines the best of both companies.For GUBamy, we also recently published strong interim clinical results from the first part of the Phase 1 Multiple-Ascending-Dose study (MAD). The results exceeded our expectations and positions GUBamy as best-in-class. The study showed that GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the previous Single-Ascending-Dose study (SAD). On weight reduction, GUBamy delivered a remarkable weight loss. Once-weekly administration for six weeks of 1 mg or 2 mg GUBamy led to a dose dependent mean weight loss compared to a weight gain in the placebo group. LS Mean weight loss in the 2 mg cohort was -7.77% compared to an LS Mean weight gain of +1.99% in the placebo arm on day 43. Data confirmed general picture from the SAD study with a high degree of consistency within cohorts. The study also confirmed the very long and favourable half-life of 11 days. The MAD study Part B for testing higher doses during a longer treatment period is ongoing and is progressing as planned.","length":1543,"tagName":"p"},{"type":"text","content":"UCN2 - next in lineAside from Amylin, we are...

More updates from Gubra A/s